This page in Swedish

Ann-Sofi Duberg

Position: Senior Lecturer School/office: School of Medical Sciences

Email: ann-sofi.duberg@oru.se

Phone: No number available

Room: X1307

Research subject

Medicine

About Ann-Sofi Duberg

Ann-Sofi Duberg is docent in infectious diseases, senior lecturer at Örebro University and consultant at the Department of Infectious Diseases at Örebro University Hospital. From autumn 2018 until start of spring semester 2022, she was the coordinator of the Programme in Medicine at Örebro University, where she previously had the overall responsibility for the medical students’ clinical placements.

Research

As physician at the Department of Infectious Diseases, Ann-Sofi Duberg’s specialty and research field have long been viral hepatitis.

She obtained her doctoral degree (2009) with a thesis on hepatitis C. She has since continued conducting studies within the field of chronic viral hepatitis, but also on primary liver cancer, also known as hepatocellular carcinoma (HCC), which is caused by chronic hepatitis B and C.

Ann-Sofi Duberg is principal supervisor of Charlotte Lybeck (specialist physician at the Department of Infectious Diseases, Örebro University Hospital) who is working on a doctoral thesis about hepatitis C screening, cancer incidence in people with hepatitis C, and long-term follow-up of patients who have undergone treatment for hepatitis C. Ann-Sofi Duberg is also assistant supervisor of two doctoral students at Karolinska Institutet: Caroline Gahrton, who is writing a thesis about hepatitis C as a result of previous or current injecting drug use; and Habiba Kamal Khodir, who is studying liver complications and death in patients with chronic hepatitis B and D.

Ann-Sofi Duberg is involved in a number of research projects relating to hepatitis B, hepatitis D and hepatitis C. A number of these are conducted in cooperation with researchers at Örebro University and Örebro University Hospital, and with colleagues at other hospitals, mainly Karolinska University Hospital in Stockholm. She is also involved in other national and international collaborative research projects, such as the Polaris network.

Teaching

Ann-Sofi Duberg has been involved on the Programme in Medicine at Örebro University since its inception in 2011. She has been the programme coordinator until January 2022, in addition she teaches and lectures on hepatitis, on the Programme in Medicine, on courses for physicians doing their specialist training, as well as on other courses and at conferences for fellow physicians.

Collaboration and assignments

Ann-Sofi Duberg is a member of the national expert committees that prepare treatment recommendations for hepatitis B and C, and she is a member of the group that drew up the Swedish clinical practice guidelines for primary liver cancer.

Ann-Sofi Duberg is chair of the national working committee for hepatitis, tasked with preparing a national plan for eliminating hepatitis B and C by 2030, in accordance with WHO goals. Other expert assignments include working on a follow-up of a campaign for hepatitis C screening of individuals receiving blood prior to 1992, for the Swedish National Board of Health and Welfare, and conducting an overview of hepatitis C infectiousness for the Public Health Agency of Sweden.

Research groups
Publications

Research groups

Hepatitis B, D och C

Publications

Articles in journals

Duberg, A. (2024). Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. Journal of Hepatology, 80 (2), 232-242.
Kamal, H. , Lindahl, K. , Ingre, M. , Gahrton, C. , Karkkonen, K. , Nowak, P. , Vesterbacka, J. , Stål, P. & et al. (2024). The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years. Liver international, 44 (1), 228-240.
Kamal, H. , Ingre, M. , Stål, P. , Westman, G. , Bruce, D. , Wedemeyer, H. , Duberg, A. & Aleman, S. (2023). Age-specific and sex-specific risks for HCC in African-born persons with chronic hepatitis B without cirrhosis. Hepatology communications, 7 (12).
Razavi-Shearer, D. , Duberg, A. , Razavi, H. & Polaris Observatory Collaborators, . (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. The Lancet Gastroenterology & Hepatology, 8 (10), 879-907.
Razavi, H. A. , Buti, M. , Terrault, N. A. , Zeuzem, S. , Yurdaydin, C. , Tanaka, J. , Aghemo, A. , Akarca, U. S. & et al. (2023). Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. Journal of Hepatology, 79 (2), 576-580.
Duberg, A. , Lybeck, C. , Fält, A. , Montgomery, S. & Aleman, S. (2022). Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study. Hepatology communications, 6 (9), 2418-2430.
Blach, S. , Duberg, A. & Razavi, H. A. (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology & Hepatology, 7 (5), 396-415.
Christensen, P. B. , Debrabant, B. , Cowan, S. , Debrabant, K. , Ovrehus, A. & Duberg, A. (2022). Hepatitis C time trends in reported cases and estimates of the hidden population born before 1965, Denmark and Sweden, 1990 to 2020. Eurosurveillance, 27 (50), 30-38.
Colombe, S. , Axelsson, M. , Aleman, S. , Duberg, A. , Lundberg Ederth, J. & Dahl, V. (2022). Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018. BMC Infectious Diseases, 22 (1).
Duberg, A. , Lybeck, C. , Fält, A. , Montgomery, S. & Aleman, S. (2022). Reply Comment on risk of HCC with chronic hepatitis B infection in Sweden. Hepatology communications, 6 (12), 3593-3594.
Blach, S. , Blomé, M. , Duberg, A. , Jerkeman, A. , Kåberg, M. , Klasa, P. , Lagging, M. , Razavi-Shearer, D. & et al. (2021). Hepatitis C Elimination in Sweden: Progress, Challenges and Opportunities for Growth in the time of COVID-19. Liver international, 41 (9), 2024-2031.
Gahrton, C. , Håkansson, A. , Kåberg, M. , Jerkeman, A. , Häbel, H. , Dalgard, O. , Duberg, A. & Aleman, S. (2021). Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. PLOS ONE, 16 (6).
Lybeck, C. , Bruce, D. , Montgomery, S. , Aleman, S. & Duberg, A. (2021). Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct-acting antivirals. GastroHep, 3 (3), 185-195.
Polaris Observatory Collaborators, -. , Razavi, H. , Blach, S. , Razavi-Shearer, D. & Duberg, A. (2021). The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 28 (1), 12-19.
Millbourn, C. , Lybeck, C. , Einberg, A. P. , Nordin, M. , Lindh, G. , Hökeberg, I. , Fredlund, H. , Fischler, B. & et al. (2020). Anti-HCV prevalence and risk factor-based screening for hepatitis C in pregnant women and their partners in Sweden. Infectious Diseases, 52 (11), 776-785.
Simon, T. G. , Duberg, A. , Aleman, S. , Chung, R. T. , Chan, A. T. & Ludvigsson, J. F. (2020). Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. New England Journal of Medicine, 382 (11), 1018-1028.
Udumyan, R. , Montgomery, S. , Duberg, A. , Fang, F. , Valdimarsdottir, U. , Ekbom, A. , Smedby, K. E. & Fall, K. (2020). Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients. Scandinavian Journal of Gastroenterology, 55 (5), 597-605.
Aleman, S. , Söderholm, J. , Büsch, K. , Kövamees, J. & Duberg, A. (2020). Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver international (Print), 40 (8), 1832-1840.
Batyrbekova, N. , Aleman, S. , Lybeck, C. , Montgomery, S. & Duberg, A. (2020). Hepatitis C virus infection and the temporal trends in the risk of liver cancer: a national register-based cohort study in Sweden. Cancer Epidemiology, Biomarkers and Prevention, 29 (1), 63-70.
Kåberg, M. , Larsson, S. B. , Jerkeman, A. , Nystedt, A. , Duberg, A. , Kövamees, J. , Ydreborg, M. , Aleman, S. & et al. (2020). High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. Scandinavian Journal of Gastroenterology, 55 (5), 574-580.
Kamal, H. , Westman, G. , Falconer, K. , Duberg, A. , Weiland, O. , Haverinen, S. , Wejstål, R. , Carlsson, T. & et al. (2020). Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology, 72 (4), 1177-1190.
Westin, J. , Aleman, S. , Castedal, M. , Duberg, A. , Eilard, A. , Fischler, B. , Kampmann, C. , Lindahl, K. & et al. (2020). Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases, 52 (1), 1-22.
Kjellin, M. , Kileng, H. , Akaberi, D. , Palanisamy, N. , Duberg, A. , Danielsson, A. , Kristiansen, M. G. , Nöjd, J. & et al. (2019). Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scandinavian Journal of Gastroenterology, 54 (8), 1042-1050.
Simon, T. G. , Duberg, A. , Aleman, S. , Hagström, H. , Nguyen, L. H. , Khalili, H. , Chung, R. T. & Ludvigsson, J. F. (2019). Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Annals of Internal Medicine, 171 (5), 318-327.
Lybeck, C. , Brenndörfer, E. D. , Sällberg, M. , Montgomery, S. , Aleman, S. & Duberg, A. (2019). Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. European Journal of Gastroenterology and Hepathology, 31 (4), 506-513.
Gahrton, C. , Westman, G. , Lindahl, K. , Öhrn, F. , Dalgard, O. , Lidman, C. , Nilsson, L. , Said, K. & et al. (2019). Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infectious Diseases, 19 (1).
Safreed-Harmon, K. , Blach, S. , Aleman, S. , Boe Kielland, K. , Bollerup, S. , Cooke, G. , Dalgard, O. , Dillon, J. F. & et al. (2019). The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination. Clinical Infectious Diseases, 69 (12), 2218-2227.
Leblebicioglu, H. , Arends, J. E. , Ozaras, R. , Corti, G. , Santos, L. , Boesecke, C. , Ustianowski, A. , Duberg, A. & et al. (2018). Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Research, 150, 9-14.
Polaris Observatory, C. & Duberg, A. (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology & Hepatology, 3 (6), 383-403.
Kileng, H. , Kjellin, M. , Akaberi, D. , Bergfors, A. , Duberg, A. , Wesslén, L. , Danielsson, A. , Gangsøy Kristiansen, M. & et al. (2018). Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. Scandinavian Journal of Gastroenterology, 53 (10-11), 1347-1353.
Razavi, H. A. , Duberg, A. & Hatzakis, A. (2017). Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The Lancet Gastroenterology & Hepatology, 2 (5), 325-336.
Einberg, A. P. , Duberg, A. , Filipovich, O. , Nyström, J. , Zhirkov, A. , Brenndörfer, E. D. , Frelin, L. , Rukoiatkina, E. & et al. (2017). Lack of association between interleukin 28B polymorphism and vertical transmission of hepatitis C. Journal of Pediatric Gastroenterology and Nutrition - JPGN, 65 (6), 608-612.
Büsch, K. , Waldenström, J. , Lagging, M. , Aleman, S. , Weiland, O. , Kövamees, J. , Duberg, A. & Söderholm, J. (2017). Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scandinavian Journal of Gastroenterology, 52 (1), 61-68.
Millbourn, C. , Lybeck, C. , Fadl, H. , Fredlund, H. , Lindahl, K. & Duberg, A. (2017). Screening for HCV in pregnant women and their partners. Journal of Hepatology, 66 (1), S404-S405.
Törner, A. , Stokkeland, K. , Svensson, Å. , Dickman, P. W. , Hultcrantz, R. , Montgomery, S. M. & Duberg, A. (2017). The underreporting of hepatocellular carcinoma to the Cancer Register and a log-linear model to estimate a more correct incidence. Hepatology, 65 (3), 885-892.
Holmström, M. , Nangarhari, A. , Öhman, J. , Duberg, A. , Majeed, A. & Aleman, S. (2016). Long-term liver-related morbidity and mortality related to chronic hepatitis C virus infection in Swedish patients with inherited bleeding disorders. Haemophilia, 22 (6), e494-e501.
Duberg, A. , Blach, S. , Falconer, K. , Kåberg, M. , Razavi, H. & Aleman, S. (2015). The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scandinavian Journal of Gastroenterology, 50 (2), 233-244.
Bruggmann, P. , Berg, T. , Ovrehus, A. L. H. , Moreno, C. , Brandao Mello, C. E. , Roudot-Thoraval, F. , Marinho, R. T. , Sherman, M. & et al. (2014). Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis, 21, 5-33.
Wedemeyer, H. , Duberg, A. , Buti, M. , Rosenberg, W. M. , Frankova, S. , Esmat, G. , Ormeci, N. , Van Vlierberghe, H. & et al. (2014). Strategies to manage hepatitis C virus (HCV) disease burden. Journal of Viral Hepatitis, 21, 60-89.
Razavi, H. , Waked, I. , Sarrazin, C. , Myers, R. P. , Idilman, R. , Calinas, F. , Vogel, W. , Mendes Correa, M. C. & et al. (2014). The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 21 (Suppl. 1), 34-59.
Duberg, A. , Hansdotter, F. , How, A. -. , Holmström, A. & Lesko, B. (2013). Angeläget med generösare provtagning för hepatit C efter blodtransfusion Socialstyrelsens nya rekommendation för riskgrupper. Läkartidningen, 110 (34-35), 1477.
Palanisamy, N. , Danielsson, A. , Kokkula, C. , Yin, H. , Bondeson, K. , Wesslén, L. , Duberg, A. & Lennerstrand, J. (2013). Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.. Antiviral Research, 99 (1), 12-17.
Huang, J. , Magnusson, M. , Törner, A. , Ye, W. & Duberg, A. (2013). Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: a nationwide study in Sweden. British Journal of Cancer, 109 (11), 2917-2923.
Lagging, M. , Duberg, A. , Wejstål, R. , Weiland, O. , Lindh, M. , Aleman, S. & Josephson, F. (2012). Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scandinavian Journal of Infectious Diseases, 44 (7), 502-521.
Törner, A. , Dickman, P. , Duberg, A. , Kristinsson, S. , Landgren, O. , Björkholm, M. & Svensson, Å. (2011). A method to visualize and adjust for selection bias in prevalent cohort studies. American Journal of Epidemiology, 174 (8), 969-76.
Hofmann, J. N. , Törner, A. , Chow, W. , Ye, W. , Purdue, M. P. & Duberg, A. (2011). Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. European Journal of Cancer Prevention, 20 (4), 326-30.
Duberg, A. , Pettersson, H. , Aleman, S. , Blaxhult, A. , Davidsdottir, L. , Hultcrantz, R. , Bäck, E. , Ekdahl, K. & et al. (2011). The burden of hepatitis C in Sweden: a national study of inpatient care. Journal of Viral Hepatitis, 18 (2), 106-118.
Törner, A. , Duberg, A. , Dickman, P. & Svensson, Å. (2010). A proposed method to adjust for selection bias in cohort studies. American Journal of Epidemiology, 171 (5), 602-608.
Davídsdóttir, L. , Duberg, A. , Törner, A. , Aleman, S. , Bäck, E. , Ekdahl, K. , Blaxhult, A. , Ekbom, A. & et al. (2010). Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country. Scandinavian journal of gastroenterology, 45 (7-8), 944-952.
Widlund, M. & Duberg, A. (2010). Hundbett gav kvarstående dövhet: Capnocytophaga canimorsus orsakade allvarlig infektion med sepsis: [Permanent hearing loss following dog bite. Capnocytophaga canimorsus caused severe infection with sepsis]. Läkartidningen, 107 (29-31), 1771-3.
Duberg, A. & Hultcrantz, R. (2009). Misleading figures on trends in mortality from hepatocellular carcinoma in Europe. Hepatology, 49 (1), 336-336.
Duberg, A. , Törner, A. , Davidsdóttir, L. , Aleman, S. , Blaxhult, A. , Svensson, Å. , Hultcrantz, R. , Bäck, E. & et al. (2008). Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. Journal of Viral Hepatitis, 15 (7), 538-550.
Strauss, R. , Törner, A. , Duberg, A. , Hultcrantz, R. & Ekdahl, K. (2008). Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden: a low endemic country. Journal of Viral Hepatitis, 15 (7), 531-537.
Duberg, A. , Janzon, R. , Bäck, E. , Ekdahl, K. & Blaxhult, A. (2008). The epidemiology of hepatitis C virus infection in Sweden. Eurosurveillance, 13 (21).
Duberg, A. , Nordström, M. , Törner, A. , Reichard, O. , Strauss, R. , Janzon, R. , Bäck, E. & Ekdahl, K. (2005). Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology, 41 (3), 652-659.
Norda, R. , Duberg, A. , Sönnerborg, A. & Olcén, P. (1995). Transmission of hepatitis C virus by transfusion in Orebro County, Sweden, 1990-1992. Scandinavian Journal of Infectious Diseases, 27 (5), 449-452.
Sjöberg, L. , Fredlund, H. & Duberg, A. (1988). A comparison between Bactec aerobic resin and hypertonic blood culture media.. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS), 96 (8), 720-722.

Articles, reviews/surveys

Kamal, H. , Fornes, R. , Simin, J. , Stål, P. , Duberg, A. , Brusselaers, N. & Aleman, S. (2021). Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. Journal of Viral Hepatitis, 28 (10), 1431-1442.
Lagging, M. , Wejstål, R. , Duberg, A. , Aleman, S. , Weiland, O. & Westin, J. (2018). Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infectious Diseases, 50 (8), 569-583.
The Polaris Observatory HCV, c. & Duberg, A. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology & Hepatology, 2 (3), 161-176.
Lindh, M. , Uhnoo, I. , Bläckberg, J. , Duberg, A. , Friman, S. , Fischler, B. , Karlström, O. , Norkrans, G. & et al. (2008). Treatment of chronic hepatitis B infection: an update of Swedish recommendations. Scandinavian Journal of Infectious Diseases, 40 (6-7), 436-450.

Chapters in books

Duberg, A. (2016). Bakterie- och parasitorsakade leversjukdomar. In: Greger Lindberg, Henry Nyhlin, Gastroenterologi och Hepatologi (pp. 253-256). Lund: Studentlitteratur AB.
Duberg, A. (2016). Virushepatiter. In: Greger Lindberg, Henry Nyhlin, Gastroenterologi och Hepatologi (pp. 247-252). Lund: Studentlitteratur AB.

Conference papers

Söderholm, J. , Larsson, S. B. , Jerkeman, A. , Nystedt, A. , Duberg, A. , Kövamees, J. , Ydreborg, M. , Aleman, S. & et al. (2019). ELEVATED RISK FOR LIVER RELATED MORTALITY IN CHRONIC HEPATITIS C PATIENTS BOTH WITH OR WITHOUT ILLICIT SUBSTANCE USE DISORDER: A NATION-WIDE REGISTER STUDY. In: Hepatology. Paper presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Boston, MA, USA, November 8-12, 2019. (pp. 366A-366A). John Wiley & Sons.
Lybeck, C. , Bruce, D. , Montgomery, S. , Aleman, S. & Duberg, A. (2018). A national study of risk for non-liver cancer in people with hepatitis C treated with direct acting antivirals or an interferon-based regimen. In: Journal of Hepatology. Paper presented at International Liver Congress (ILC), Paris, France, April 11-15, 2018. (pp. S263-S264). Elsevier.
Simon, T. G. , Duberg, A. , Aleman, S. , Hagström, H. , Chung, R. T. & Ludvigsson, J. F. (2018). Lipophilic Statins and Risk of Hepatocellular Carcinoma and Mortality: A Prospective, Nationwide Population with Chronic Viral Hepatitis. In: Hepatology. Paper presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, USA, November 9-13, 2018. (pp. 59A-60A). John Wiley & Sons.
Kamal, H. , Falconer, K. , Westman, G. , Duberg, A. , Weiland, O. R. H. J. , Wejstal, R. , Carlssson, T. , Kampmann, C. & et al. (2018). Long-Term Liver-Related Outcomes in Hepatitis B and D Co-Infected Patients in Sweden. In: Hepatology. Paper presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, USA, November 9-13, 2018. (pp. 1190A-1191A). John Wiley & Sons.
Gahrton, C. , Lindahl, K. , Westman, G. , Öhrn, F. , Dalgard, O. , Duberg, A. , Lidman, C. , Said, K. & et al. (2018). Prevalence of viremic hepatitis C virus, hepatitis B virus, or HIV infection and vaccination status among Swedish prisoners. Paper presented at 7th International Symposium on Hepatitis Care in Substance Users (INHSU), Cascais, Portugal, September 19-21, 2018.
Duberg, A. , Lybeck, C. , Fält, A. , Wedemeyer, H. , Montgomery, S. & Aleman, S. (2018). The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden. In: Journal of Hepatology. Paper presented at International Liver Congress (ILC), Paris, France, April 11-15, 2018. (pp. S488-S488). Elsevier.
Särnblad, S. , Lidskog, M. , Walfridsson, H. , Hjelmqvist, H. & Duberg, A. (2018). Will Early Clinical Training improve the professional skills?: Experience from a New Medical Education in Sweden. Paper presented at AMEE (An International Association for Medical Education), Basel, Switzerland, 25-29 August, 2018.
Kileng, H. , Kjellin, M. , Bergfors, A. , Duberg, A. , Wesslen, L. , Danielsson, A. , Kristiansen, M. G. , Gutteberg, T. & et al. (2016). Effect of pre-existing Hepatitis C NS3 Q80K variant in Genotype la and NS5A Y93H variant in Genotype 3 for interferon-free treatment combinations with direct antiviral agents (DAAs): Real-life experience from a multicenter study in Sweden and Norway. In: Hepatology. Paper presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, USA, November 11-15, 2016. (pp. 1001A-1001A). John Wiley & Sons.

Doctoral theses, comprehensive summaries

Duberg, A. (2009). Hepatitis C virus infection: a nationwide study of associated morbidity and mortality. (Doctoral dissertation). (Comprehensive summary) Örebro: Örebro universitet.

Manuscripts

Udumyan, R. , Montgomery, S. , Duberg, A. , Fang, F. , Valdimarsdottir, U. , Ekbom, A. , Smedby, K. E. & Fall, K. Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients.
Malm, K. , Duberg, A. , Sundqvist, M. , Fredlund, H. & Andersson, S. Evaluation of a hepatitis C virus core antigen assay to monitor viral load in patients on antiviral therapy and in untreated patients.
Lybeck, C. , Bruce, D. , Montgomery, S. , Aleman, S. & Duberg, A. Risk of hepatocellular carcinoma after DAA treatment and association with pretreatment liver stiffness in a national hepatitis C cohort.
Duberg, A. , Pettersson, H. , Aleman, S. , Blaxhult, A. , Davidsdottir, L. , Hultcrantz, R. , Bäck, E. , Ekdahl, K. & et al. The burden of hepatitis C in Sweden : a national study of inpatient care.